ATRX — Adhera Therapeutics Share Price
Last Trade - 00:00Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.08 | 0.25 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adhera Therapeutics, Inc., formerly Marina Biotech, Inc., is a specialty pharmaceutical company that provides patient centric treatment for hypertension. The Company develops and commercializes pharmaceutical therapies and provides technology to improve patient outcomes. It is also focused on developing and commercializing late-stage, non-addictive pain therapeutics. It provides Celecoxib-Lisinopril fixed dose combination (IT-102) and Celecoxib-Olmesartan fixed dose combination (IT-103), which are designed to control the side-effect of edema that prohibits the drug from being prescribed at higher doses. IT-102 targets a population requiring angiotensin converting enzyme (ACE) inhibitors, such as lisinopril and IT-103 targets a population requiring olmesartan. The Company is also focused on commercializing perindopril arginine and amlodipine besylate (PRESTALIA) through DyrctAxess, which is a patient-centric treatment platform.
Directors
- Andrew Kucharchuk (39)
- Isaac Blech
- Erik Emerson DRC (48)
- Charles Rice (56)
- Trond Waerness (53)
- Donald Williams (61)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- September 23rd, 1983
- Public Since
- April 15th, 1994
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 11,630,709
- Address
- P.O. Box 2161, WAKE FOREST, 27588
- Web
- https://adherathera.com/
- Phone
- +1 9195785901
- Auditors
- BAKER TILLY US LLP
Latest News for ATRX
Upcoming events for ATRX
Similar to ATRX
ADVANTIS ORD
Pink Sheets on Nasdaq
ADYNXX ORD
Pink Sheets on Nasdaq
AFFYMAX ORD
Pink Sheets on Nasdaq
AMARANTUS BIOSCIENCE HOLDINGS ORD
Pink Sheets on Nasdaq
AMERICAN CRYOSTEM ORD
Pink Sheets on Nasdaq
FAQ
As of Today at 19:56 UTC, shares in Adhera Therapeutics are trading at $0.14. This share price information is delayed by 15 minutes.
Shares in Adhera Therapeutics last closed at $0.14 and the price had moved by +42.86% over the past 365 days. In terms of relative price strength the Adhera Therapeutics share price has outperformed the S&P500 Index by +10.51% over the past year.
There is no consensus recommendation for this security.
Adhera Therapeutics does not currently pay a dividend.
Adhera Therapeutics does not currently pay a dividend.
Adhera Therapeutics does not currently pay a dividend.
To buy shares in Adhera Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.14, shares in Adhera Therapeutics had a market capitalisation of $1.63m.
Here are the trading details for Adhera Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ATRX
Based on an overall assessment of its quality, value and momentum Adhera Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adhera Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +28.56%.
As of the last closing price of $0.14, shares in Adhera Therapeutics were trading +66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Adhera Therapeutics.
Adhera Therapeutics' management team is headed by:
- Andrew Kucharchuk -
- Isaac Blech -
- Erik Emerson - DRC
- Charles Rice -
- Trond Waerness -
- Donald Williams -
We do not have data on Adhera Therapeutics' shareholders